Argenx initiates second cohort of phase 2 arda study of empasiprubart in multifocal motor neuropathy

Independent data monitoring committee recommend ed study continuation based on the favorable safety profile observed in the first dose cohort early efficacy signals support proof-of-concept of empasiprubart in multifocal motor neuropathy regulated information/inside information amsterdam, the netherlands—june 20, 2023—argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to advance to a second dose cohort with the phase 2 arda study of empasiprubart (argx-117) in multifocal motor neuropathy (mmn). the decision follows a planned interim analysis of the first dose cohort by an independent data monitoring committee (idmc) meeting held on june 19, 2023.
ARGX Ratings Summary
ARGX Quant Ranking